A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

NCT01173497 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Estrogen Receptor Negative (ER-Negative) Breast Cancer
Progesterone Receptor Negative (PR-Negative) Breast Cancer
Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer
Brain Metastases

Interventions

DRUG: INIPARIB + irinotecan

Sponsor

Sanofi

Collaborators

[object Object]